These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

854 related items for PubMed ID: 27808588

  • 1. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
    Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A.
    Gynecol Endocrinol; 2017 Jan; 33(1):39-42. PubMed ID: 27808588
    [Abstract] [Full Text] [Related]

  • 2. Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study.
    Tagliaferri V, Romualdi D, Immediata V, De Cicco S, Di Florio C, Lanzone A, Guido M.
    Clin Endocrinol (Oxf); 2017 May; 86(5):725-730. PubMed ID: 28092404
    [Abstract] [Full Text] [Related]

  • 3. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
    Zhao H, Xing C, Zhang J, He B.
    Reprod Health; 2021 Aug 18; 18(1):171. PubMed ID: 34407851
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
    Cappelli V, Di Sabatino A, Musacchio MC, De Leo V.
    Minerva Ginecol; 2013 Aug 18; 65(4):425-33. PubMed ID: 24051942
    [Abstract] [Full Text] [Related]

  • 8. The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.
    Soldat-Stanković V, Popović-Pejičić S, Stanković S, Prtina A, Malešević G, Bjekić-Macut J, Livadas S, Ognjanović S, Mastorakos G, Micić D, Macut D.
    J Endocrinol Invest; 2022 Mar 18; 45(3):583-595. PubMed ID: 34665453
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial.
    Shokrpour M, Foroozanfard F, Afshar Ebrahimi F, Vahedpoor Z, Aghadavod E, Ghaderi A, Asemi Z.
    Gynecol Endocrinol; 2019 May 18; 35(5):406-411. PubMed ID: 30608001
    [Abstract] [Full Text] [Related]

  • 11. [Molecular action of insulin-sensitizing agents].
    Kacalska O, Krzyczkowska-Sendrakowska M, Milewicz T, Zabińska-Popiela M, Bereza T, Krzysiek-Maczka G, Krzysiek J.
    Endokrynol Pol; 2005 May 18; 56(3):308-13. PubMed ID: 16350724
    [Abstract] [Full Text] [Related]

  • 12. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
    Kriplani A, Agarwal N.
    J Reprod Med; 2004 May 18; 49(5):361-7. PubMed ID: 15214709
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition].
    Le Donne M, Alibrandi A, Giarrusso R, Lo Monaco I, Muraca U.
    Minerva Ginecol; 2012 Feb 18; 64(1):23-9. PubMed ID: 22334228
    [Abstract] [Full Text] [Related]

  • 15. Inositols in Polycystic Ovary Syndrome: An Overview on the Advances.
    Facchinetti F, Unfer V, Dewailly D, Kamenov ZA, Diamanti-Kandarakis E, Laganà AS, Nestler JE, Soulage CO, Group of 'Inositol in PCOS and Reproduction'.
    Trends Endocrinol Metab; 2020 Jun 18; 31(6):435-447. PubMed ID: 32396844
    [Abstract] [Full Text] [Related]

  • 16. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
    Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, Schmidt M, Elsenbruch S, Kimmig R, Mann K, Janssen OE.
    Eur J Endocrinol; 2007 Nov 18; 157(5):669-76. PubMed ID: 17984248
    [Abstract] [Full Text] [Related]

  • 17. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.
    Fux Otta C, Wior M, Iraci GS, Kaplan R, Torres D, Gaido MI, Wyse EP.
    Gynecol Endocrinol; 2010 Mar 18; 26(3):173-8. PubMed ID: 20148739
    [Abstract] [Full Text] [Related]

  • 18. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
    Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M.
    J Clin Endocrinol Metab; 2000 Jan 18; 85(1):139-46. PubMed ID: 10634377
    [Abstract] [Full Text] [Related]

  • 19. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome.
    Donà G, Sabbadin C, Fiore C, Bragadin M, Giorgino FL, Ragazzi E, Clari G, Bordin L, Armanini D.
    Eur J Endocrinol; 2012 Apr 18; 166(4):703-10. PubMed ID: 22223702
    [Abstract] [Full Text] [Related]

  • 20. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
    Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M.
    J Clin Endocrinol Metab; 2011 May 18; 96(5):E821-4. PubMed ID: 21307134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.